Abstract
The present global endeavor to uncover the most effective vaccines against severe acute respiratory syndrome coronavirus (SARS-CoV-2) that can tremendously prevent transmission, infection and significantly reduce public health risk. COVID-19 vaccination program is underway in different parts of the world including Bangladesh but till to date there is no available health data revealed among the vaccinated peoples. We conducted a cross-sectional study from February 15 to April 15, 2021 to assess the health status of 1st dose Oxford-AstraZeneca vaccinated individuals infected with SARS CoV-2. Standard virological method, real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) was performed to detect SARS-CoV-2 and the different health parameters from vaccinated individuals were collected through direct mobile phone contact using pre-structured questionnaires. A total of 6146 suspected samples were tested and 1752 were found positive for SARS-CoV-2, of them 200 individuals were identified who received 1st dose of COVID-19 vaccine. Within the test period, majority of male (65.6%) and female (34.4%) carried moderate numbers of viruses which comprise between 30.01-35 cyclic threshold (ct) values. Among the vaccinated individuals, 165 (82.5%; 95% CI: 76.51 - 87.5) persons were not hospitalized and 177 (88.5%; 95% CI: 83.24 - 92.57) did not show any respiratory difficulties. Only a few (16) (8%; 95% CI: 4.64 - 12.67) of COVID-19 positive patients needed extra oxygen support and 199 (99.5%; 95% CI: 97.25 - 99.99) individuals didn’t require any intensive care unit (ICU) interference. Overall, oxygen saturation was recorded around 96.8% and respiratory difficulties did not extend more than 5 days, irrespective of age and sex during the infection period. Within the vaccinated COVID-19 positive individuals 113 (56.5%; 95% CI: 49.33 - 63.48) and 111(55.5%; 95% CI: 48.32 - 62.51) persons have normal physiological taste and smell. However, we have found a larger proportion of vaccinated persons (129) (64.5%; 95% CI: 57.44 - 71.12) carrying different comorbidity, among them high blood pressure 36 (27.9%; 95% CI, 20.37 - 36.48) and diabetes 32 (24.8%; 95% CI: 17.63 - 33.18) were found more prevalent. Moreover, the significant finding of the present study was 199 (99.5%; 95% CI: 97.25 - 99.99) vaccinated individuals survived with good health conditions and became negative in RT-qPCR. The authors suggest that health risk assessment among the COVID-19 vaccinated persons when infected with SARS-CoV-2 is crucial and time demanding task for the whole world. However, the present study illustrates that the administration of the 1st dose Oxford-AstraZeneca vaccine significantly reduces health risk during the COVID-19 infection period.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors acknowledge CMC and BITID for providing samples from different regions of the Chattogram division. The authors also acknowledge Fahad Hossain Palash and Md. Jahid Hasan for collecting patients data. The laboratory reagent facilities were supported by the Directorate General of Health Services, Peoples Republic of Bangladesh. The authors sincerely acknowledge the Director, Poultry Research and Training Centre (PRTC), CVASU for laboratory logistic support. The study was funded by the Director of Research & Extension, CVASU.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee (EC) of CVASU
This is to certify that, the project “Severity assessment of single-dose Oxford-AstraZeneca vaccinated individuals infected with SARS CoV-2 in the Southeast Bangladesh” being investigated by Prof. Dr. Goutam Buddha Das, CVASU COVID-19 Lab, CVASU has met the necessary requirements of its Chattogram Veterinary and Animal Sciences University Ethics Committee to carry out the project activities. The CVASU Ethics Committee approval number for the project is Memo no.-CVASU/Dir(R&E)EC/2021/244(1), Date: 09/05/2021.
The details of the Ethical Committee (EC)
1. Prof. Dr. Paritosh Kumar Biswas, Department of Microbiology and Veterinary Public Health and Director of Poultry Research and Training Center, CVASU - Chairman
2. Prof. Dr. Mohammad Rashedul Alam, Department of Physiology Biochemistry and Pharmacology, CVASU - Member
3. Prof. Dr. Md. Farid Ahsan, Department of Zoology, Chittagong University - Member
4. Mr. Md. Habibur Rahman Bhuiyan, Principal Staff Officer (PSO), Bangladesh Council of Scientific and Industrial Research (BCSIR) - Member
5. Dr. Jahangir Alam Chowdhury, Physical Medicine, Chattogram Maa-O-Shishu Hospital Medical College - Member
6. DR. Quazi Roksana Sultana, Senior Medical Officer, CVASU - Memeber
7. Prof. Dr. Md. Ashraf Ali Biswas, Directorate of Research & Extension, CVASU - Member of Secretariat
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Co-authors: EAR: eaftekhar{at}cvasu.ac.bd, PD: proneshdutta92{at}gmail.com, TAN: tanvir.vet{at}gmail.com, TD: tridipdas{at}cvasu.ac.bd, SC: sharminchowdhury{at}cvasu.ac.bd, GBS: gbmadhu07{at}yahoo.com
Data Availability
The data availabilty link is not given.
